These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36562460)

  • 1. Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
    Preusser M; van den Bent MJ
    Neuro Oncol; 2023 Apr; 25(4):631-634. PubMed ID: 36562460
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
    Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
    JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
    Hdeib A; Sloan AE
    CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination.
    Pasqualetti F; Zanotti S
    Br J Cancer; 2023 Oct; 129(6):895-896. PubMed ID: 36792723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
    Olivier T; Migliorini D
    Rev Neurol (Paris); 2023 Jun; 179(5):502-505. PubMed ID: 37012085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
    Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
    J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
    Gatto L; Di Nunno V; Tosoni A; Bartolini S; Ranieri L; Franceschi E
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCVax-Brain and DC vaccines in the treatment of GBM.
    Wheeler CJ; Black KL
    Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor regression following autologous tumor lysate-loaded dendritic cell vaccination immunotherapy: illustrative case.
    Kamaludin AI; Sibtain N; Ashkan K
    J Neurosurg Case Lessons; 2024 Jul; 8(2):. PubMed ID: 38976918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.
    Fishman M
    Expert Opin Biol Ther; 2009 Dec; 9(12):1565-75. PubMed ID: 19916735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
    Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
    J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: DCVax, Northwest Biotherapeutics.
    Knutson KL
    Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
    Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.
    Prins RM; Soto H; Konkankit V; Odesa SK; Eskin A; Yong WH; Nelson SF; Liau LM
    Clin Cancer Res; 2011 Mar; 17(6):1603-15. PubMed ID: 21135147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.
    Prins RM; Cloughesy TF; Liau LM
    N Engl J Med; 2008 Jul; 359(5):539-41. PubMed ID: 18669440
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.